Abstract

To explore the clinical efficacy and safety of ceftriaxone sodium plus Xiaoyan Lidan tablets for the treatment of acute cholecystitis. 78 acute cholecystitis individuals were consecutively selected and were divided into monotherapy group (n=36) and combination group (n=42). Monotherapy group was treated with ceftriaxone sodium while combination group were treated with Xiaoyan Lidan tablets along with ceftriaxone sodium. Clinical efficacy, resolution time of clinical symptoms/signs, hospital length of stay and the incidence of adverse reactions of the two groups were compared and recorded. Maximal long-axis and short-axis diameter of gallbladder and the gallbladder wall thickness were measured by color Doppler ultrasonography. Besides, serum indirect bilirubin and total bile acid levels were determined with the use of an automatic biochemical analyzer. Furthermore, enzyme-linked immunosorbent assay was carried out to quantify serum interleukin-6, C-reactive protein and tumor necrosis factor-alpha levels. An evidently lower overall response rate was determined in the monotherapy group compared with the combination group. Symptoms such as epigastric pain, resolution time, fever relief time, nausea and vomiting improvement time and hospital length of stay were significantly shorter in the combination group vs. monotherapy group. Combination group had lower post-treatment gallbladder tension, serum indirect bilirubin, total bile acid, interleukin-6, C-reactive protein and tumor necrosis factor-alpha levels than the monotherapy group; both the groups had similar incidence of adverse reactions. Combined effect of ceftriaxone sodium with Xiaoyan Lidan tablets is effective and safe in treating acute cholecystitis and can significantly reduce inflammatory reactions in the body, facilitating patient recovery.